Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis

Anna Giménez‐Palomo; Anjli K. Chamdal; Natalie Gottlieb; Mojtaba Lotfaliany; Tahir Jokinen; Eslam M. Bastawy; Katherine Adlington; Nawal Benachar; Seetal Dodd; Isabella Pacchiarotti; Eduard Vieta; Michael Berk; Paul Stokes

doi:10.1111/acps.13728

Shared by

Eduard Vieta

Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis

Article 2024 en

Authors

AG
Anna Giménez‐Palomo
AC
Anjli K. Chamdal
NG
Natalie Gottlieb

Abstract

1 min read

MAOIs are similar in efficacy to other antidepressants for the treatment of depression. However, more studies are needed comparing MAOI treatment in people with treatment-resistant, atypical and bipolar depression.

Related publications

Article2024

Author response for "Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis"

Anna Giménez‐Palomo, Anjli K. Chamdal, Natalie Gottlieb, Mojtaba Lotfaliany, Tahir Jokinen, Eslam M. Bastawy, Katherine Adlington, Nawal Benachar, Seetal Dodd, Isabella Pacchiarotti, Eduard Vieta, Michael Berk, Paul Stokes

Article2024

Author response for "Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis"

Article2003

Atypical antipsychotics in the treatment of mood disorders

Eduard Vieta

Article2022

The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression

Vincent Van den Eynde, Wegdan R. Abdelmoemin, Magid M. Abraham, Jay D. Amsterdam, Ian Anderson, Chittaranjan Andrade, Glen B. Baker, Aartjan T.F. Beekman, Michael Berk, Tom K. Birkenhäger, Barry Blackwell, Pierre Blier, Marc B.J. Blom, Alexander J. Bodkin, C Cattaneo, Bezalel Dantz, Jonathan Davidson, Boadie W. Dunlop, Ryan F. Estévez, Shalom S. Feinberg, J. P. M. Finberg, Laura J. Fochtmann, David Gotlib,

Article2008

Ziprasidone in the Treatment of Affective Disorders: A Review

Adriane Ribeiro Rosa, Carolina Franco, Carla Torrent, Mercé Comes, Núria Cruz, Guillermo Horga, Antonio Benabarre, Eduard Vieta

Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis

Abstract

Discussion(0)

Related publications

Author response for "Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis"

Author response for "Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis"

Atypical antipsychotics in the treatment of mood disorders

The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression

Ziprasidone in the Treatment of Affective Disorders: A Review